Market Overview

UPDATE: William Blair Initiates Coverage on Pharmacyclics on Good Market Position for Ibrutinib

Related PCYC
Pharmacyclics Enters Into Agreement With Roche To Evaluate IMBRUVICA And GAZYVA In Lymphoma And Leukemia
Pharmacyclics and Servier Agree To Conclude Pan-HDAC Inhibitor Collaboration

In a report published Tuesday, William Blair & Company analyst Y. Katherine Xu initiated coverage on Pharmacyclics (NASDAQ: PCYC) with an Outperform rating and $143.00 price target.

In the report, William Blair & Company noted, “Pharmacyclics' ibrutinib is positioned to be the first of a new wave of agents ready to transform the treatment of B-cell malignancies, and we believe ibrutinib could become the largest product in hematology oncology history. We rate Pharmacyclics Outperform with a price target of $143 based on the following: 1) ibrutinib's mechanism of action allows it to address almost all B-cell malignancies, the largest patient pool among hematological malignancies; 2) ibrutinib has the best combined efficacy and safety profile among competitors and is also the first to market; 3) expanding indications as well as pushing usage from the relapsed/refractory setting to the frontline and maintenance settings will result in a gradual increase of treatment duration, which translates into increased sales potential; 4) ibrutinib's profile should allow it to become the preferred backbone for future combination regimens; and 5) there is a lack of competition within the class of BTK inhibitors.”

Pharmacyclics closed on Monday at $120.76.

Latest Ratings for PCYC

Sep 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Aug 2014Wallachbeth CapitalUpgradesHoldBuy
Aug 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for PCYC
View the Latest Analyst Ratings

Posted-In: William Blair & Company Y. Katherine XuAnalyst Color Initiation Analyst Ratings


Related Articles (PCYC)

Around the Web, We're Loving...

Get Benzinga's Newsletters